Anti-TROP-2 Antibody-drug Conjugate HS-20105

**Semantic type:** Pharmacologic Substance

**Definition:** An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting the tumor-associated antigen (TAA) trophoblast cell surface protein 2 (trophoblast antigen 2; calcium signal transducer 2; TROP2; TROP-2; TACSTD2; GA733-1; M1S1) linked, via a cleavable linker, to a camptothecin derivative and topoisomerase-1 inhibitor, with potential antineoplastic activity. Upon administration of anti-TROP-2 ADC HS-20105, the anti-TROP-2 antibody targets and binds to TROP-2 expressed on tumor cells. Upon binding, internalization and linker cleavage, the topoisomerase-1 inhibitor is released, and inhibits DNA topoisomerase-1 activity, thereby inhibiting DNA replication and resulting in cell cycle arrest and tumor cell apoptosis. This inhibits the proliferation of TROP-2-expressing tumor cells. TROP-2 is a transmembrane protein overexpressed in various tumors. Its expression is associated with enhanced tumor aggressiveness, metastasis, drug resistance and increased tumor cell survival.

**Synonyms:** - ADC HS-20105 - Anti-TROP-2 ADC HS-20105 - Anti-TROP-2/Topoisomerase-1 Inhibitor ADC HS-20105 - HS 20105 - HS-20105 - HS20105